OPKO Health (LTS:0KCS) Growth Rank: 1 (As of Aug. 02, 2026) — 67% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0KCS OPKO Health Inc LTS:0KCS
58 GF Score
Price $1.34
GF Value $1.13
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is OPKO Health Growth Rank?

OPKO Health LTS:0KCS -0.01% 58 Growth Rank is 1 as of Aug. 02, 2026, which is 67% below its 10-year median of 3.00. GuruFocus rates LTS:0KCS with a GF Score™ of 58/100 and a GF Value™ of $1.13 (Modestly Overvalued). The stock has 5 warning signs investors should review.

OPKO Health has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

LTS:0KCS vs CSTL, FRNM, PSNL: Growth Rank Comparison

For the Diagnostics & Research subindustry, OPKO Health's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OPKO Health Growth Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's Growth Rank distribution charts can be found below:

* The bar in red indicates where OPKO Health's Growth Rank falls into.


LTS:0KCS
58GF Score
OPKO Health Inc LTS:0KCS
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
OPKO Health (LTS:0KCS) has a Growth Rank of 1 as of Aug. 02, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on OPKO Health and its competitors. This is 67% below median its historical median of 3.00. Over the past decade, OPKO Health's Growth Rank has ranged from 1.00 to 8.00.
Is OPKO Health's Growth Rank too high?
OPKO Health's current Growth Rank of 1 is 67% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. Overall, OPKO Health has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OPKO Health's Growth Rank compare to CSTL and FRNM?
OPKO Health's Growth Rank of 1 can be compared against companies in the Medical Diagnostics & Research industry. Historically, OPKO Health's own Growth Rank has ranged from 1.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Diagnostics & Research company?
A good Growth Rank depends on the Medical Diagnostics & Research industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on OPKO Health and its competitors. OPKO Health's current Growth Rank is 1, which is 67% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OPKO Health stock overvalued right now?
Based on GuruFocus' analysis, OPKO Health (LTS:0KCS) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.13, compared to a current price of $1.34 — trading 18.6% above its estimated fair value. The current Growth Rank is 1, which is 67% below median its 10-year median of 3.00. OPKO Health's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For OPKO Health (LTS:0KCS), the current Growth Rank is 1 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OPKO Health (LTS:0KCS) Overvalued in 2026?

Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued. The current stock price of $1.34 is trading 18.6% above its estimated GF Value™ of $1.13. GuruFocus considers OPKO Health to be Modestly Overvalued.

Key valuation signals for LTS:0KCS:

  • Growth Rank: 1 (67% below median its 10-year median of 3.00)
  • GF Value™: $1.13 vs. price of $1.34 (18.6% above fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the LTS:0KCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OPKO Health Business Description

Address 4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
58GF Score

Get the complete analysis for LTS:0KCS

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.34
Price
$1.13
GF Value